Search
Xinjing Zhiyuan and BeiGene Sign Licensing Agreement for Next-Generation Universal Cell Therapy Drug Development
2025-06-03 /
Read about 0 minute
Author：小编
Xinjing Zhiyuan and BeiGene have inked a non-exclusive licensing agreement, empowering BeiGene to leverage its proprietary antigen-specific TCR molecules in the development of novel universal cell therapy drugs. In exchange, Xinjing Zhiyuan will receive upfront payments, milestone achievements-based payments, and sales royalties. This collaboration builds upon Xinjing Zhiyuan's advanced CAST® database, underscoring its robust technological prowess and promising commercial potential in TCR discovery. Both entities aim to broaden the treatment landscape for cancer patients.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
